News Report | May 19, 2023
DEA Delays Ending Controlled-Substances Prescribing Flexibilities, Virtual MAT Can Continue Through November 2024
On May 11, 2023, the Drug Enforcement Administration (DEA) and the Substance Abuse and Mental Health Services Administration (SAMHSA) implemented a temporary rule to extend telemedicine flexibilities adopted during the COVID-19 public health emergency (PHE). Virtual medication-assisted treatment (MAT) for opioid addiction, for treatment relationships established before or on November 11, 2023, can continue through November 11, 2024. Under this rule, the full set of telemedicine flexibilities regarding prescription of controlled medications that were in place during the COVID-19 PHE will remain in place through November 11, 2023.
The COVID-19-related flexibilities allowed consumers to initiate . . .